Shiwei Jin

机构：Shanghai Jiao Tong University, Ruijin Hospital, Gene Therapy Laboratory, Shanghai Institute of Hematology, Shanghai Cell Therapy Research Institute · ORCID：0009-0003-4560-537X

发表论文 28 篇 · 总被引 348 次 · h-index 7

代表论文

• Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2) (2022 · Journal of Hematology & Oncology · 被引 144)
• PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion (2024 · Journal for ImmunoTherapy of Cancer · 被引 56)
• Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma (2024 · Nature Communications · 被引 48)
• Updated Phase 1 Results of a First-in-Human Open-Label Study of Lcar-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (Bcma) (2019 · Blood · 被引 27)
• Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma (2024 · BMC Cancer · 被引 12)
• Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2. (2023 · Journal of Clinical Oncology · 被引 8)